Orexo AB (publ) (ORX.ST)
SEK 20.8
(-5.24%)
SEK 20.8
(-5.24%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 549.9 Million SEK | -9.37% |
| 2022 | 521.7 Million SEK | 7.32% |
| 2021 | 486.1 Million SEK | -18.71% |
| 2020 | 598 Million SEK | -19.1% |
| 2019 | 739.2 Million SEK | 20.92% |
| 2018 | 611.3 Million SEK | 27.54% |
| 2017 | 479.3 Million SEK | -13.83% |
| 2016 | 556.2 Million SEK | 9.65% |
| 2015 | 507.25 Million SEK | 9.59% |
| 2014 | 462.87 Million SEK | 15.72% |
| 2013 | 400.01 Million SEK | 34.05% |
| 2012 | 298.4 Million SEK | 74.9% |
| 2011 | 170.61 Million SEK | -7.36% |
| 2010 | 184.17 Million SEK | -13.31% |
| 2009 | 212.45 Million SEK | -1.6% |
| 2008 | 215.9 Million SEK | 1400.97% |
| 2007 | 14.38 Million SEK | -89.95% |
| 2006 | 143.1 Million SEK | 119.13% |
| 2005 | 65.3 Million SEK | -22.97% |
| 2004 | 84.78 Million SEK | 349.98% |
| 2003 | 18.84 Million SEK | 1350.5% |
| 2002 | 1.29 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 105.4 Million SEK | -15.61% |
| 2024 Q2 | 116.9 Million SEK | 10.91% |
| 2024 Q3 | 116.4 Million SEK | -0.43% |
| 2023 Q3 | 133.3 Million SEK | -5.12% |
| 2023 Q4 | 124.9 Million SEK | -6.3% |
| 2023 FY | 472.8 Million SEK | -9.37% |
| 2023 Q2 | 140.5 Million SEK | 7.99% |
| 2023 Q1 | 130.1 Million SEK | 0.0% |
| 2022 Q1 | 131.8 Million SEK | 6.55% |
| 2022 Q2 | 126.6 Million SEK | -3.95% |
| 2022 Q3 | 133 Million SEK | 5.06% |
| 2022 Q4 | 130.1 Million SEK | -2.18% |
| 2022 FY | 521.7 Million SEK | 7.32% |
| 2021 FY | 486.1 Million SEK | -18.71% |
| 2021 Q1 | 113.1 Million SEK | -23.53% |
| 2021 Q2 | 124.7 Million SEK | 10.26% |
| 2021 Q4 | 123.7 Million SEK | -0.72% |
| 2021 Q3 | 124.6 Million SEK | -0.08% |
| 2020 Q3 | 135.8 Million SEK | -14.7% |
| 2020 Q1 | 155 Million SEK | -27.91% |
| 2020 FY | 598 Million SEK | -19.1% |
| 2020 Q2 | 159.2 Million SEK | 2.71% |
| 2020 Q4 | 147.9 Million SEK | 8.91% |
| 2019 Q2 | 169.9 Million SEK | 14.03% |
| 2019 Q3 | 205.3 Million SEK | 20.84% |
| 2019 Q4 | 215 Million SEK | 4.72% |
| 2019 FY | 739.2 Million SEK | 20.92% |
| 2019 Q1 | 149 Million SEK | -18.89% |
| 2018 Q3 | 174.2 Million SEK | 7.46% |
| 2018 FY | 611.3 Million SEK | 27.54% |
| 2018 Q2 | 162.1 Million SEK | 77.55% |
| 2018 Q4 | 183.7 Million SEK | 5.45% |
| 2018 Q1 | 91.3 Million SEK | -35.16% |
| 2017 Q3 | 134.1 Million SEK | 8.85% |
| 2017 Q2 | 123.2 Million SEK | 51.72% |
| 2017 Q1 | 81.2 Million SEK | -46.05% |
| 2017 FY | 479.3 Million SEK | -13.83% |
| 2017 Q4 | 140.8 Million SEK | 5.0% |
| 2016 FY | 556.2 Million SEK | 9.65% |
| 2016 Q3 | 143.6 Million SEK | -6.87% |
| 2016 Q2 | 154.2 Million SEK | 30.13% |
| 2016 Q1 | 118.5 Million SEK | -39.54% |
| 2016 Q4 | 150.5 Million SEK | 4.81% |
| 2015 FY | 507.25 Million SEK | 9.59% |
| 2015 Q1 | 116.3 Million SEK | -37.16% |
| 2015 Q2 | 90.1 Million SEK | -22.53% |
| 2015 Q3 | 104.7 Million SEK | 16.2% |
| 2015 Q4 | 196 Million SEK | 87.2% |
| 2014 Q2 | 92.5 Million SEK | 8.7% |
| 2014 Q4 | 185.07 Million SEK | 84.52% |
| 2014 FY | 462.87 Million SEK | 15.72% |
| 2014 Q3 | 100.3 Million SEK | 8.43% |
| 2014 Q1 | 85.1 Million SEK | -11.27% |
| 2013 Q1 | 132.9 Million SEK | 74.4% |
| 2013 Q2 | 61.9 Million SEK | -53.42% |
| 2013 Q4 | 95.91 Million SEK | -12.17% |
| 2013 Q3 | 109.2 Million SEK | 76.41% |
| 2013 FY | 400.01 Million SEK | 34.05% |
| 2012 FY | 298.4 Million SEK | 74.9% |
| 2012 Q4 | 76.2 Million SEK | 9.8% |
| 2012 Q2 | 76.1 Million SEK | -0.78% |
| 2012 Q3 | 69.4 Million SEK | -8.8% |
| 2012 Q1 | 76.7 Million SEK | 64.81% |
| 2011 FY | 170.61 Million SEK | -7.36% |
| 2011 Q4 | 46.53 Million SEK | 14.21% |
| 2011 Q3 | 40.75 Million SEK | -15.66% |
| 2011 Q2 | 48.31 Million SEK | 38.01% |
| 2011 Q1 | 35.01 Million SEK | -65.57% |
| 2010 Q3 | 30.27 Million SEK | 36.44% |
| 2010 Q1 | 30.03 Million SEK | 39.33% |
| 2010 FY | 184.17 Million SEK | -13.31% |
| 2010 Q2 | 22.19 Million SEK | -26.12% |
| 2010 Q4 | 101.67 Million SEK | 235.81% |
| 2009 FY | 212.45 Million SEK | -1.6% |
| 2009 Q1 | 109.26 Million SEK | 24.26% |
| 2009 Q2 | 23.1 Million SEK | -78.86% |
| 2009 Q3 | 58.52 Million SEK | 153.34% |
| 2009 Q4 | 21.55 Million SEK | -63.17% |
| 2008 Q3 | 56.63 Million SEK | 0.0% |
| 2008 Q4 | 87.93 Million SEK | 55.27% |
| 2008 FY | 215.9 Million SEK | 1400.97% |
| 2007 FY | 14.38 Million SEK | -89.95% |
| 2006 FY | 143.1 Million SEK | 119.13% |
| 2005 FY | 65.3 Million SEK | -22.97% |
| 2004 FY | 84.78 Million SEK | 349.98% |
| 2003 FY | 18.84 Million SEK | 1350.5% |
| 2002 FY | 1.29 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AcuCort AB | 6.59 Million SEK | -8241.93% |
| AlzeCure Pharma AB (publ) | -476 Thousand SEK | 115625.21% |
| BioGaia AB (publ) | 950.19 Million SEK | 42.127% |
| Enzymatica AB (publ) | 31.86 Million SEK | -1625.826% |
| Enorama Pharma AB (publ) | -3.9 Million SEK | 14196.386% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | -9000.00 SEK | 6110100.0% |
| Moberg Pharma AB (publ) | -2.09 Million SEK | 26298.19% |
| Nanexa AB (publ) | 59.15 Million SEK | -829.56% |
| Newbury Pharmaceuticals AB (publ) | 16.03 Million SEK | -3329.801% |
| ODI Pharma AB | -1.34 Million SEK | 41087.303% |
| Probi AB (publ) | 220.21 Million SEK | -149.713% |
| Swedencare AB (publ) | 164.8 Million SEK | -233.677% |
| Swedish Orphan Biovitrum AB (publ) | 14.05 Billion SEK | 96.087% |
| Toleranzia AB | -919 Thousand SEK | 59936.779% |
| Vivesto AB | -10.65 Million SEK | 5260.473% |